170 related articles for article (PubMed ID: 22640598)
1. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.
Koskela-Niska V; Lyytinen H; Riska A; Pukkala E; Ylikorkala O
Climacteric; 2013 Feb; 16(1):48-53. PubMed ID: 22640598
[TBL] [Abstract][Full Text] [Related]
2. Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland.
Koskela-Niska V; Riska A; Lyytinen H; Pukkala E; Ylikorkala O
Gynecol Oncol; 2012 Aug; 126(2):241-4. PubMed ID: 22561401
[TBL] [Abstract][Full Text] [Related]
3. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer--a population-based case control study from Finland.
Koskela-Niska V; Pukkala E; Lyytinen H; Ylikorkala O; Dyba T
Int J Cancer; 2013 Oct; 133(7):1680-8. PubMed ID: 23526244
[TBL] [Abstract][Full Text] [Related]
4. Hormone therapy and different ovarian cancers: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjaer SK; Lidegaard O
Am J Epidemiol; 2012 Jun; 175(12):1234-42. PubMed ID: 22517811
[TBL] [Abstract][Full Text] [Related]
5. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study.
Jaakkola S; Lyytinen HK; Dyba T; Ylikorkala O; Pukkala E
Int J Cancer; 2011 Apr; 128(7):1644-51. PubMed ID: 21280035
[TBL] [Abstract][Full Text] [Related]
6. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
7. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.
Korhonen K; Auvinen A; Lyytinen H; Ylikorkala O; Pukkala E
Am J Epidemiol; 2012 Feb; 175(4):309-14. PubMed ID: 22287638
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Death Risk in Relation to the Age at Initiation or the Progestin Component of Hormone Therapies.
Savolainen-Peltonen H; Tuomikoski P; Korhonen P; Hoti F; Vattulainen P; Gissler M; Ylikorkala O; Mikkola TS
J Clin Endocrinol Metab; 2016 Jul; 101(7):2794-801. PubMed ID: 27172432
[TBL] [Abstract][Full Text] [Related]
9. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
10. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer.
Jaakkola S; Pukkala E; K Lyytinen H; Ylikorkala O
Int J Cancer; 2012 Aug; 131(4):E537-43. PubMed ID: 22024969
[TBL] [Abstract][Full Text] [Related]
12. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk in postmenopausal women using estrogen-only therapy.
Lyytinen H; Pukkala E; Ylikorkala O
Obstet Gynecol; 2006 Dec; 108(6):1354-60. PubMed ID: 17138766
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
15. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.
Shi LF; Wu Y; Li CY
Menopause; 2016 Apr; 23(4):417-24. PubMed ID: 26506499
[TBL] [Abstract][Full Text] [Related]
16. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
Johannisson E; Holinka CF; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
[TBL] [Abstract][Full Text] [Related]
17. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy and ovarian borderline tumors: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjær SK; Lidegaard Ø
Cancer Causes Control; 2012 Jan; 23(1):113-20. PubMed ID: 22037908
[TBL] [Abstract][Full Text] [Related]
19. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland.
Lyytinen H; Dyba T; Pukkala E; Ylikorkala O
Int J Cancer; 2010 Jul; 127(1):185-9. PubMed ID: 19859914
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the central effects of different progestins used in hormone replacement therapy.
Cagnacci A; Arangino S; Baldassari F; Alessandrini C; Landi S; Volpe A
Maturitas; 2004 Aug; 48(4):456-62. PubMed ID: 15283939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]